Vera Therapeutics (VERA) share were up more than 2% in recent Thursday trading after the clinical-stage biotechnology company reported its Q3 results.
Earlier, Vera reported a Q3 net loss of $0.85 per diluted share, compared with a loss of $0.45 a year ago. Analysts polled by Capital IQ expected a loss of $0.66.
As expected, no revenue for the quarter ended Sept. 30 was reported.
The company said its balance sheet will be sufficient to fund operations through the potential approval and US commercial launch of atacicept.
Price: 49.02, Change: +1.08, Percent Change: +2.25
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments